Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial

Study Overview
=================
Brief Summary
-----------------
The primary objectives of this trial are: To compare the safety of oral rifabutin versus placebo in the treatment of Mycobacterium avium complex (MAC) bacteremia in AIDS patients with CD4 counts less than or equal to 200 cells/mm3. To investigate the incidence of MAC in these patients. A secondary objective is to compare clinical response, quality of life (Karnofsky), and survival between these two groups.

Official Title
-----------------
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial

Conditions
-----------------
Mycobacterium Avium-intracellulare Infection, HIV Infections

Intervention / Treatment
-----------------
* Drug: Rifabutin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Patients must have the following: Diagnosis of AIDS with a case defining infection other than Mycobacterium avium complex (MAC). Written informed consent. Females of childbearing potential must also sign a special informed consent. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: Known hypersensitivity to rifabutin, rifampin, other rifamycins, zidovudine or didanosine (ddI). Previous or current infection due to Mycobacterium avium complex (MAC) disease as evaluated by two successive blood cultures and two successive stool cultures taken within 14 days prior to study initiation. Concurrent Medication: Excluded: Antiretroviral agents other than zidovudine (AZT). Didanosine (ddI). Antimycobacterial therapy. Rifampin. Isoniazid. Clofazimine. Ethambutol. Cycloserine. Ethionamide. Amikacin. Ciprofloxacin. Streptomycin. Other investigational drugs. If antimicrobial therapy is required to treat bacterial infections (= or < 14 days), Adria Laboratories must be contacted prior to initiation of therapy. Patients with the following are excluded: Known hypersensitivity to rifabutin, rifampin, other rifamycins, zidovudine (AZT), or didanosine (ddI). Previous or current Mycobacterium avium complex (MAC) infection. Perceived patient unreliability or unavailability for frequent monitoring. Prior Medication: Excluded within 4 weeks of study entry: Antiretroviral agents other than zidovudine (AZT) or didanosine (ddI). Antimycobacterial therapy. Rifampin. Isoniazid. Clofazimine. Ethambutol. Cycloserine. Ethionamide. Amikacin. Ciprofloxacin. Required: Zidovudine (AZT). Antipneumocystis prophylactic therapy. Required for at least 4 weeks prior to study entry: Zidovudine (AZT) or didanosine (ddI). Antipneumocystis prophylaxis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Rifabutin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Rifabutin, AIDS-Related Opportunistic Infections, Mycobacterium avium-intracellulare Infection, Acquired Immunodeficiency Syndrome, Antitubercular Agents